Table 3.
Biochemical FFR and OS for Patients Receiving 2 Years of Combined Androgen Blockade in S9921 Control Arm
| Risk Group | No. | 5-Year FFR |
5-Year OS |
||
|---|---|---|---|---|---|
| % | 95% CI | % | 95% CI | ||
| All patients in ADT arm | 481 | 92.5 | 90.0 to 95.0 | 95.9 | 93.9 to 97.9 |
| High (node positive) | 79 | 83.2 | 73.8 to 92.6 | 92.3 | 85.6 to 99.0 |
| Intermediate (Gleason score ≥ 8 or stage T3b) | 277 | 92.2 | 88.7 to 95.7 | 96.8 | 94.6 to 99.0 |
| Low (Gleason score 7 with positive margins or PSA > 10) | 125 | 99.1 | 97.3 to 100 | 95.9 | 91.8 to 100 |
Abbreviations: FFR, freedom from relapse; OS, overall survival; ADT, androgen deprivation therapy; PSA, prostate-specific antigen.